Algonomics’ liver cancer treatment ‘RZ-001’ has been designated by the FDA as a regenerative medicine advanced therapy (RMAT). The drug targets hTERT, which is expressed in more than 80% of cancer cells, and is currently in a phase 1b/2a clinical trial. The company plans to accel
2026-05-15
Ilyang Pharmaceutical has completed dosing in the North American phase 1/2a trial of NG101, a gene therapy for wet age-related macular degeneration designated for the FDA’s Fast Track program. NG101 is designed to provide long-term effects with a single administration, improving
2026-05-15
Orum Therapeutics raised 145 billion won in follow-on funding in January this year to advance development of next-generation antibody-drug conjugates (DACs). The funds will be used for preclinical research on follow-on pipelines for the TPD² platform based on GSPT1 degraders. The
2026-05-15
Vaxcell-Bio has completed an advanced regenerative medicine clinical study of the NK cell therapy 'Vax-NK' in 12 patients with small cell lung cancer and submitted a results report to the Ministry of Health and Welfare. The study evaluated safety by administering Vax-NK in combin
2026-05-15
The United States will impose a 100% tariff on imported patented medicines, with the measure applying to large companies starting July 31. To receive a tariff exemption, companies must submit detailed U.S. production plans, including investment and production schedules, by June 1
2026-05-15
Asymptomatic people with mpox appear to drive transmission, with only 1 in 33 infected people—about 3%—being diagnosed. Kaiser Permanente researchers analyzed samples from more than 8,000 men and found that about 1% had asymptomatic infections without knowing it, contradicting th
2026-05-15
Huons BioPharma’s botulinum toxin LIZTOX has completed product approval for the indication of treating upper-limb muscle spasticity after stroke. This expansion into therapeutic applications follows two aesthetic indications, while a phase 3 clinical trial is also underway to imp
2026-05-15
Huons is advancing 12 pipelines, including a phase 3 clinical trial of a glaucoma treatment. Its subsidiary Huons N has successfully completed a human application trial of a fatigue-relief ingredient and applied for approval of three individually recognized ingredients, including
2026-05-15
Bristol Myers Squibb (BMS) has signed a drug development agreement with China’s Hengrui Pharma worth up to $15.2 billion (approximately 22 trillion won). BMS secured global rights outside China to four candidates in Hengrui Pharma’s oncology pipeline, while Hengrui Pharma obtaine
2026-05-15
In 2024, 64% of delays in new drug launches were found to stem from chemistry, manufacturing and controls (CMC) issues. The delays were analyzed as resulting from the complex production processes for biologics, which account for 55% of the overall clinical pipeline. The industry
2026-05-15
